Picture: Charnwood Molecular

Charnwood Molecular with new CEO

Lee Patterson joins UK-based Charnwood Molecular as new CEO. After nearly 25 years at UK-based Charnwood Molecular, Prof. Steve Allin has stepping down as CEO. He will remain as an investor and Board advisor.

Lee Patterson joins Charnwood Molecular with extensive experience gained across the drug discovery sector. Most recently this included senior executive leadership roles at Concept Life Sciences and Covance. He also brings a scientific background in Pathological and Biomedical Sciences.

This appointment comes after the company recently added a DMPK department alongside bioscience, medicinal chemistry, computational chemistry and process research and development. Based in world-class facilities at Charnwood Campus, Charnwood Molecular is ideally placed as the integrated discovery and development CRO of choice for global clients.

In 2022 Charnwood Molecular relocated its BioCity and Loughborough operations to a single-site, state-of-the-art laboratory complex based in world-class facilities at Charnwood Campus, Loughborough. The campus was recently designated a “Life Sciences Opportunity Zone”, providing an environment to inspire discovery, encourage collaboration and accelerate business growth within the Med-Tech and Biopharma industries.

From founding the business as a Loughborough University spin-out, alongside Prof. Phil Page in 1998, to ultimately supporting the acquisition of Charnwood Molecular by global growth investor, Synova, in 2019, Steve Allin has been at the forefront of the company’s growth and development. He will remain as an investor and Board advisor.